/ Protocol Intelligence
ALAR · v2.4
3 agents active 1 review pending Patient burden: moderate
LT
ALAR-ONC-042 — Phase II NSCLC
Pembrolizumab + Investigational · v2.4 draft · Last edited 2h ago · 3 contributors
Amendment risk
58 / 100
Moderate
Patient burden
62 / 100
Moderate
Precedents12
Draft editor
Agent review4
Change control
Outputs5
12 precedents matched · sorted by protocol similarity
96% match
KEYNOTE-189: Pembrolizumab + Chemo in Metastatic NSCLC
NCT02578680 · Phase III · FDA approved 2018 · 616 participants
PD-1 inhibitorNon-squamousICR landmarkAmendment x2
89% match
KEYNOTE-024: Pembrolizumab vs Platinum Chemo (PD-L1 ≥50%)
NCT02142738 · Phase III · FDA approved 2016 · 305 participants
PD-L1 enriched1L NSCLCClean protocol
81% match
CHECKMATE-227: Nivolumab + Ipilimumab in Advanced NSCLC
NCT02477826 · Phase III · BMS · 1739 participants
Dual ICIAll-comers PD-L1Amendment x4
74% match
EMPOWER-Lung 1: Cemiplimab Monotherapy in NSCLC
NCT03088540 · Phase III · Regeneron · 710 participants
Anti-PD-1Robust eligibilityLow patient burden
4.2 Eligibility Criteria
Adults (≥18 years) with histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC) with stage IIIB–IV disease at screening, who have received no prior systemic therapy for advanced disease.
Participants must have an ECOG performance status of 0 or 1, and a tumor specimen with assessable PD-L1 expression status from a site-approved laboratory.
4.3 Exclusion Criteria
Participants with active, known, or suspected autoimmune disease. History of significant cardiovascular disease within 6 months. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.
5.1 Primary Endpoint
Progression-free survival (PFS) per RECIST v1.1 as assessed by Blinded Independent Central Review (BICR), defined as the time from randomization to first documented disease progression or death from any cause, whichever occurs first.
[ Continue drafting Section 5.2 — Secondary Endpoints… ]
AI suggestions
Eligibility risk
Age cutoff not defined for elderly subgroup. KEYNOTE-189 included a secondary stratum for ≥70 with dose modifications.
Apply suggestion ↗
PD-L1 assay!
FDA flagged unspecified assay type in 3 of 4 comparable submissions. Specify 22C3 pharmDx (Dako) as required platform.
Fix language ↗
Endpoint alignment
PFS definition matches RECIST v1.1 standard. BICR requirement consistent with FDA guidance (2022).
Patient burden flag!
22 scheduled visits across Cycles 1–4 exceeds precedent average of 16. Bone imaging frequency may drive dropout risk.
Optimize schedule ↗
7
Total findings
2
High risk · amendment
3
Patient burden flags
↓42%
vs. avg amendments
Eligibility Agent
2 warnings · review required
Age cutoff undefined for elderly subgroup (≥70). Missing stratification language per FDA 2021 guidance.
ref: KEYNOTE-189 §4.1 · FDA Guidance 2021-CGD-04
PD-L1 assay platform unspecified. Ambiguity flagged in 3 comparable IND submissions.
ref: NCT02578680, NCT02142738 amendment logs
Consistency Agent
1 critical · cross-section conflict
§4.3 exclusion "significant cardiovascular disease" conflicts with §8.2 Grade 3+ safety reporting definition.
ref: Internal cross-reference §4.3 ↔ §8.2
Primary endpoint (§5.1) BICR and RECIST v1.1 references complete and correctly versioned.
Patient Burden Agent
3 flags · burden score 62/100
22 total on-site visits across Cycles 1–4 exceeds precedent average of 16. High dropout risk in elderly subgroup.
ref: KEYNOTE-189 SoE · dropout analysis §14.2
Bone imaging required every cycle — consider Q2-cycle frequency per CHECKMATE-227 precedent.
ref: NCT02477826 SoE §9.9
Pregnancy test frequency (Q3W) exceeds FDA minimum guidance. Reducing to Q6W lowers burden without compliance risk.
ref: FDA Oncology Guidance 2020-R1 §4.3
Regulatory Agent
All checks passed
IND reference documents cited. FDA 2022 guidance on IO endpoint alignment incorporated.
ICH E6(R3) GCP requirements addressed. Risk-based monitoring language included.
EMA alignment checked. No divergence from EU CTR submission requirements identified.
Protocol history · ALAR-ONC-042
v2.4 — Eligibility & PD-L1 assay update
Pending QA review · LT · 2h ago
Draft
Agent review flagged 2 high-risk issues. §4.2 PD-L1 assay specification and elderly stratification require resolution before submission.
v2.3 — Schedule & follow-up interval
Approved · AP · 3 days ago
Approved
Long-term follow-up adjusted from Q8W to Q12W. LTFU endpoint windows updated. No regulatory impact assessed.
v2.2 — Primary endpoint clarification
Approved · GV · 9 days ago
Approved
BICR language added to §5.1 per FDA alignment. RECIST version number clarified.
Submission timeline
Precedent search
12 precedents identified
Complete · Mar 10
Protocol drafted
v2.3 approved, v2.4 in progress
Complete · Mar 18
Agent review
7 findings · 2 unresolved
In progress · Est. Mar 27
Sponsor QA sign-off
Pending review completion
Target: Apr 3
IND submission
Target: Apr 10
Generated outputs · ALAR-ONC-042 · v2.4
📋
Protocol synopsis
Structured 6-page synopsis with all key design decisions source-linked to precedent protocols and regulatory guidance.
14 sources cited
85%
🔍
Amendment risk report
Audit-ready report summarizing agent findings, risk scores, and recommended revisions with full source traceability.
7 findings
Ready
📝
Informed consent draft
Plain-language ICF aligned to eligibility criteria and schedule of events. Readability grade 8.
Pending §4.2 fix
Blocked
🏛
Regulatory strategy memo
FDA Type B meeting preparation memo covering endpoint design, PD-L1 assay specification, and risk mitigation strategy.
Not generated
Generate ↗
Appendix A — Schedule of Events
ALAR-ONC-042 · Group 1 Arm 1 · Pembrolizumab IV + Investigational PO · Screening, Cycle 1 & Cycle 2 · Protocol Amendment No. 5 US v1
Burden 62 / 100 3 flags
Study period Screening Treatment phase — Cycle 1 Treatment phase — Cycle 2
Cycle day ≤21 d C1D1C1D8C1D15C1D22 C2D1C2D8C2D15C2D22
Window allowed 0±2 d±2 d±2 d ±2 d±2 d±2 d±2 d
Consent & administration
Informed consent & subject ID card issued
Eligibility criteria
Demographics
Medical history
Prior medication & treatment history
Dosing
Pembrolizumab infusion
Investigational agent PO
Physical & vital assessments
Height and weight
ECOG performance status
Physical examination
Vital signs
12-lead ECG
Diary card
Imaging assessments (local)
Bone imaging ⚠ burden flag(X)
Additional at investigator discretion (suspected new / PD lesions)Additional assessments for bone disease to be done at discretion of investigator — Section 9.9.2
Extramedullary disease imaging(X)
Additional per imaging scheduleAdditional assessments for extramedullary disease per imaging schedule — Section 9.9
Clinical assessment of imaging response / statusAdditional assessments to be done per the imaging schedule — Section 9.9
Safety laboratory assessments (local analysis)
Chemistry(X)
Hematology(X)
Thyroid function
Viral serologies
Urinalysis
Pregnancy test ⚠ burden flag
ABO blood group & Rh factor; Coombs tests
AE & concomitant medication monitoring
Monitoring of concomitant medications & proceduresRecorded from signing of the ICF through 30 days after last dose of study drug or the start of subsequent anticancer therapy, whichever occurs first.
AE reportingRecorded from signing of the ICF through 30 days after last dose of study drug or the start of subsequent anticancer therapy, whichever occurs first.
SAE reportingSAEs will be reported from signing of the ICF through 30 days after last dose of study drug, even if the patient starts non-protocol therapy.
⚡ Static demo preview — UI shell only, not wired to live backend Open TrialMind Chat ↗